S

Sanofi

Global pharma company; vaccines and R&D

RWE Scientist

Full-TimeUpdated on 10/13/2026Deadline 10/21/26
€70.8k - €94.4k/yr
Senior
Bachelor's
Barcelona, Spain
Hybrid
Biology & BiotechQuantitative Biology & Biostatistics

About the job

Requirements
  • An advanced degree in pharmaco-epidemiology, biostatistics, Health Outcomes, or an equivalent discipline.
  • A minimum of 7 years of real-world evidence generation in or for the pharmaceutical industry.
  • Knowledge of real-world evidence and its application to pharmaceutical development, regulatory approval, and patient access at an international level.
  • Understanding of product development processes across all stages of the product life cycle to influence the appropriate use of real-world evidence activities.
  • Experience using innovative real-world evidence methodologies to address evidence gaps.
  • Cross-functional collaboration and alignment in complex global matrix teams.
  • Expertise in pharmacoepidemiology, health economics and outcomes research, and real-world evidence study designs and methodologies, including innovative techniques.
  • Experience working with routinely collected healthcare data, including claims databases, electronic medical health records, registries, and structured or unstructured sources within pharmaceutical company settings.
  • Ability to translate business needs into study and data requirements.
  • Experience with project management of real-world studies and management reporting.
  • Fluency in spoken and written business English is mandatory.
Responsibilities
  • Partner with and support Real-World Evidence Strategy Leads on the design, execution, analysis, interpretation, and internal and external communication of specific epidemiological and outcomes research studies.
  • Provide strategic input, epidemiological and outcomes research support, and leadership to project teams and the Real-World Data and Evidence Synthesis Team throughout pharmaceutical development.
  • Deliver specialized research to enhance real-world evidence contributions to regulatory submissions and the drug research process across discovery, development, and commercialization.
  • Support end-to-end execution of real-world studies, ensuring deliverables are timely, within budget, on specification, and scientifically rigorous.
  • Provide innovative thinking on the design of clinical and epidemiological or outcomes research programs supporting commercialization.
  • Set standards for the utilization of real-world evidence and provide methodological leadership and input to real-world evidence strategies.
  • Identify and validate fit-for-purpose external data sources and associated institutions or organizations in collaboration with the Real-World Data and Evidence Synthesis Team.
  • Provide support to the Real-World Evidence Team and the company in a specific epidemiological or outcomes research area and typically a specific therapy area.
  • Maintain timely communication and alignment with team members, partners, and stakeholders regarding evidence strategy, study progress, challenges, and risk mitigation.
  • Work with partners and stakeholders to identify optimal and efficient solutions and optimize resources and efforts.
Desired Qualifications
  • Experience in transplant, type 1 or type 2 diabetes, and cardiovascular therapeutic areas is highly preferred.
  • Proficiency or working knowledge of French or other European languages.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...

U.S. Securities and Exchange Commission
Sep 20th, 2026
8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)